GRI Bio Inc GRI.OQ GRI.O is expected to report resultson August 12 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for GRI Bio Inc is for a loss of $1.31 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for GRI Bio Inc is $102.00, about 98.8% above its last closing price of $1.25
This summary was machine generated August 8 at 15:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)